
    
      This is a study to evaluate the efficacy, safety, tolerability and pharmacokinetics of
      JTT-251 administered for 24 weeks in participants with pulmonary arterial hypertension (PAH).
      Participants completing this study (RELIEF-PAH) will be eligible to enroll in an open-label
      extension study (RELIEF-PAH OLE) to evaluate the long-term efficacy, safety, tolerability and
      pharmacokinetics of JTT-251 in participants with PAH.
    
  